Steve Barsh is Dreamit’s Chief Innovation Officer and works closely with Dreamit’s portfolio of more than 90 early stage digital health and medical device companies. Dreamit focuses on getting post-seed companies to their Series A using a highly pragmatic and impactful approach, including an extensive multi-city customer immersion process and a highly curated bi-coastal investor road show. Steve has over 30 years of experience starting, leading, launching, and building multi-national companies as well as early stage venture work. He has helped launch over 100 companies that have generated over $1B in value. As well Steve is a special advisor to NASA for their annual cross-industry innovation summit.
The availability of innovative technologies affords us the opportunity to chart a more patient-centric, efficient, and secure path to managing and leveraging PHI.
Cost management is one of the most important healthcare benefit issues for clients right now. How are you guiding and advising your clients in the costly areas of drug/specialty pharmacy, cancer care, and more? Take part in our survey and share your insights!
Optimizing care journeys based on patient needs and using collaborative resources outside of the ED can result in effective and efficient behavioral care, regardless of volume.
Ilant Health extended its seed round from $3 million to $5.5 million. The company garnered interest from LifeX Ventures, Celtic House Asia Partners and Cornucopian Capital.
The FDA expanded the approval of Roche’s Alecensa to include adjuvant treatment of non-small cell lung cancer. The targeted therapy addresses cancers driven by the ALK genetic mutation.
The imperative to modernize healthcare communication methods extends beyond mere technological upgrades. Rather, it’s a fundamental necessity to enhance patient care, streamline healthcare delivery, and unlock the full potential of medical innovation.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Medicare's Chronic Care Management program reduced emergency room and in-patient hospital visits and lowered total health spending, but uptake has been sluggish for a variety of reasons.
A much diminished 23andMe exists today, a far cry from the phenomenon that it was in the world consumer DNA testing. Could things have unfolded differently under a different leader with a different vision?
Major malpractice verdicts have spiked in recent years.
Cerevel Therapeutics drug tavapadon met the main and secondary goals of a pivotal Parkinson’s disease clinical trial. That drug and others will join the neuroscience portfolio of AbbVie, which is in the process of acquiring Cerevel.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Q1 2024 saw a significant rise in the number of hospital M&A deals compared to the past three Q1s. Experts believe this M&A activity will continue to climb throughout this year and next — motivated by both financial distress and hospitals’ desire to improve strategic business lines like value-based care and digital healthcare services.
Included Health's new specialty care clinic, which will become available in 2025, is starting by offering three centers: the Cancer Center, the Center for Women’s Health and the Center for Metabolic Health.
Achieving strong cybersecurity is a vast, interconnected web that must incorporate the correct software, procedures, and workflows and take into account the human element across an entire organization.
The recall comes years after surgeons say they first noticed problems with the HeartMate II and HeartMate 3, manufactured by Thoratec Corp., a subsidiary of Abbott Laboratories. The devices are not currently being removed from the market.
This week, the FTC ordered Cerebral to pay a $7 million fine, accusing the company of mishandling users’ sensitive health data and misleading consumers about cancellation policies. Experts agree that other virtual healthcare providers need to work on their legal and compliance strategies in order to avoid a similar fate.